Skip to main content
. 2023 Jun 5;23:374. doi: 10.1186/s12879-023-08332-7

Table 4.

Summary of serology results by primary series and booster dose status — fall academic semester 2021, Wisconsin

Vaccine profile Anti-S Anti-N Anti-S Anti-N
Primary series received N Median 95% CI Median 95% CI Vaccine platform Median 95% CI Median 95% CI
Unvaccinated 13 -0.29 (-0.52, 2.04) 0.0 (-0.77, 0.53) n/a -- -- -- --
Fully vaccinated with primary series only
 CoviShield (AstraZeneca) 5 1.99 -- -0.63 -- Vector-based 2.35 (2.06, 2.44) -0.32 (-0.70, -0.07)
 Johnson & Johnson 15 2.41 (2.13, 2.45) -0.29 (-0.70, 0.09)
 Moderna 63 2.83 (2.71, 2.90) -0.59 (-0.77, -0.50) mRNA 2.80 (2.74, 2.86) -0.56 (-0.61, -0.46)
 Pfizer 88 2.78 (2.66, 2.87) -0.51 (-0.62, -0.36)
 Covaxin 1 2.01 -- 0.50 -- Inactivated whole virus 1.87 (1.69, 2.00) 1.10 (0.99, 1.30)
 Sinopharm 33 1.66 (1.39, 1.94) 1.02 (0.62, 1.25)
 Sinovac 45 1.95 (1.82, 2.20) 1.21 (1.02, 1.42)
Primary series and mRNA booster
 CoviShield (AstraZeneca) 0 -- -- -- -- Vector-based 4.01 -- 0.29 --
 Johnson & Johnson 5 4.01 -- -0.22 --
 Moderna 8 4.07 (-0.52, 4.31) 0.42 (-1.30, 0.77) mRNA 3.82 (3.61, 3.96) -0.14 (-0.70, 0.08)
 Pfizer 20 3.69 (3.57, 3.88) -0.47 (-0.98, -0.03)
 Covaxin 1 3.20 -- 1.22 -- Inactivated whole virus 3.27 -- 0.29 --
 Sinopharm 7 3.31 -- 0.07 --
 Sinovac 2 3.45 -- 0.45 --

Anti-S Antibody levels targeting the spike protein of SARS-CoV-2. Anti-N Antibody levels targeting the nucleocapsid of SARS-CoV-2. 95% CI 95% confidence interval around the median value for each group, which are not calculated for groups with N≤10. Antibody levels are presented in WHO-standardized binding antibody units per milliliter (BAU/mL), log(10) scale